6533b832fe1ef96bd129a335
RESEARCH PRODUCT
Destination Therapy with Left Ventricular Assist Devices in Non-transplant Centres: The Time is Right
Christian Muñoz-guijosaPau CodinaCosme García-garcíaEvelyn Santiago-vacasJosep LupónJulio NúñezAntoni Bayes-genisSantiago Monterosubject
Cardiac transplantlcsh:Diseases of the circulatory (Cardiovascular) systemmedicine.medical_specialtyCardiomyopathy030204 cardiovascular system & hematologyoutcomes03 medical and health sciences0302 clinical medicineInternal medicineleft ventricular assist deviceDiseases of the circulatory (Cardiovascular) systemMedicine030212 general & internal medicineMyocardial infarctionStrokeHeart Failurebusiness.industryMortality rateAtrial fibrillationmedicine.diseaseequipment and supplieslcsh:RC666-701RC666-701Heart failureCirculatory systemCardiologydestination therapyCardiology and Cardiovascular MedicinebusinessDestination therapydescription
For almost half a century, cardiac transplant has been the only long-term treatment for patients with end-stage heart failure. Implantable left ventricular assist devices (LVADs) have emerged as a new treatment option for advanced heart failure as destination therapy for patients either too old or not suitable for transplant. A meta-analysis presenting head-to-head comparisons of cardiac transplant versus LVAD as destination therapy (LVAD-DT) found no difference in 1-year mortality rates between LVAD-DT and cardiac transplant (OR 1.49; 95% CI [0.48–4.66]; I2=82.8%). Moreover, a recent subanalysis from the Interagency Registry for Mechanically Assisted Circulatory Support found similar outcomes after LVAD-DT implantation in both transplant and non-transplant centres. The time is right for LVAD-DT in non-transplant centres, provided multidisciplinary heart failure teams and expertise are in place.
year | journal | country | edition | language |
---|---|---|---|---|
2020-04-01 | European Cardiology Review |